Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2022-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of CD19-Directed
Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with
relapsed/refractory acute lymphoblastic leukemia（ALL）.